---
title: How I treat Blastic Plasmacytoid Dendritic Cell Neoplasm
date: '2024-10-07'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39374520/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20241007200551&v=2.18.0.post9+e462414
source: Blood
description: Historically, treatment options for blastic plasmacytoid dendritic cell
  neoplasm (BPDCN) were limited to conventional chemotherapy, adopted from regimens
  used to treat acute myeloid or acute lymphoblastic leukemias, or lymphomas. Nowadays,
  a novel therapy targeting CD123 is available to treat BPDCN. Yet, regardless of
  treatment choice, achieving a first complete remission (CR1) represents the main
  goal of therapy, because it represents the best opportunity to prolong survival
  in BPDCN, ...
disable_comments: true
---
Historically, treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN) were limited to conventional chemotherapy, adopted from regimens used to treat acute myeloid or acute lymphoblastic leukemias, or lymphomas. Nowadays, a novel therapy targeting CD123 is available to treat BPDCN. Yet, regardless of treatment choice, achieving a first complete remission (CR1) represents the main goal of therapy, because it represents the best opportunity to prolong survival in BPDCN, ...